Walgreens agrees to pay $100 mln to resolve lawsuit over generic drug pricing
By Brendan Pierson
Nov 4 (Reuters) -Walgreens WBA.O has agreed to pay $100 million to settle a proposed class action lawsuit accusing it of fraudulently overcharging customers for a decade when they bought generic drugs through private insurance, Medicare or Medicaid.
Walgreens was accused of wrongly requiring insured customers to pay more than members of its Prescription Savings Club, who for a low annual fee could buy more than 500 widely prescribed generic drugs for $5, $10 and $15 for 30-day prescriptions, and $10, $20 and $30 for 90-day prescriptions without using insurance.
In a filing on Friday in federal court in Chicago, lawyers for the class of plaintiffs suing the drugstore chain sought approval for the settlement, calling it an "excellent result" for the class.
"We admit no liability and believe these claims never had any merit," a Walgreens spokesperson said in a statement. "This resolution allows us to focus on our turnaround strategy that will benefit our patients, customers, team members and shareholders."
The lawsuit alleged that the prices Walgreens charged to its savings club members were its "usual and customary" prices, and that the prices it reported to insurers for reimbursement were inflated. It said that insured customers reasonably believed that they would not pay more than customers who paid out of pocket, but they did end up paying more in the form of copays and deductibles.
The lawsuit sought damages for insured customers nationwide since 2007, when the Prescription Savings Club began.
One condition of the settlement was that Walgreens end the savings club, which it did in August.
The case is Russo et al v. Walgreen Co., U.S. District Court for the Eastern District of Illinois, No. 1:17-cv-02246.
For plaintiffs: Paul Geller of Robbins Geller Rudman & Dowd, Joseph Guglielmo of Scott + Scott and others
For Walgreens: Selina Coleman and Michael Scott Leib of Reed Smith
Read more:
Walgreen must face lawsuit over U.S. generic drug pricing
(Reporting By Brendan Pierson in New York)
</body></html>Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
